FMC63 is an @entity9749 mouse monoclonal antibody belonging to the @entity6440 cluster. @entity6440 antibodies react with a 95kDa protein expressed by cells of the B lymphocyte lineage, from pre-B cells to mature B lymphocytes. @entity6440 antibodies have been suggested as candidates for immunological attack on leukaemic and @entity706 cells of the B lineage because the antigen is restricted to the B lineage. With the potential use of FMC63 in immunotherapy in mind, we have produced a @entity19 - @entity1 chimera in which the genes coding for the VDJ region of the heavy chain and the VJ region of the light chain derive from the FMC63 @entity19 hybridoma, while the C region genes code for human @entity6527 . The genes have been transfected back into a @entity19 @entity1582 line, which secretes low levels of immunoglobulin. (Ig). This Ig was purified and biotinylated in order to determine the specificity of the antibody. The chimeric antibody has a reaction profile concordant with the original FMC63 antibody, but has the properties of a human @entity6527 , including the ability to fix @entity1 complement. However, the antibody is not cytotoxic in vitro in the presence of complement or cells capable of mediating antibody-dependent cellular @entity137 . Possible reasons for this and ways of using the antibody are discussed.

Preparation and characterization of a chimeric XXXX monoclonal antibody.

@entity1 :: ('9606', 'Species') :: ['human'] @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma'] @entity19 :: ('10090', 'Species') :: ['mouse'] @entity6527 :: ('105243590', 'Gene') :: ['IgG1'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['myeloma'] @entity9749 :: ('668478(Tax:10090)', 'Gene') :: ['IgG2a'] @entity6440 :: ('12478(Tax:10090)', 'Gene') :: ['CD19']
@entity6440 :: (12478(Tax:10090),Gene) :: ['CD19']
